ArticleFrontiers in cardiovascular medicine2026
Analysis of risk factors for early recurrence after radiofrequency ablation in patients with atrial fibrillation and construction of a nomogram predictive model.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early recurrence of atrial fibrillation (AF) after radiofrequency catheter ablation remains common and undermines procedural success. This study aimed to identify clinical, echocardiographic, and biochemical predictors of early atrial tachyarrhythmia recurrence and to construct a nomogram for individualized risk assessment. Methods: This retrospective cohort study included 276 consecutive patients with AF undergoing first-time radiofrequency catheter ablation between January 2021 and December 2024. Early recurrence was defined as any documented AF, atrial flutter, or atrial tachycardia lasting ≥30 s within 3 months post-procedure. All patients received short-term oral amiodarone for 3 months to cover the 90-day blanking period. Multivariable logistic regression was used to identify independent predictors. A nomogram was developed using the rms package in R. Discrimination was assessed using the area under the receiver operating characteristic curve (AUC). Internal validation and calibration were assessed using bootstrap resampling (1,000 iterations) with an optimism-corrected concordance index (C-index) and calibration plots, and clinical utility was evaluated using decision curve analysis (DCA). Results: Univariate analysis showed higher body mass index (BMI), larger left atrial diameter (LAD), higher B-type natriuretic peptide (BNP) levels, and higher prevalences of dyslipidemia, obstructive sleep apnea syndrome (OSAS), and persistent AF in patients with early recurrence (all Conclusions: Elevated BMI, enlarged LAD, increased BNP, persistent AF, and OSAS independently predict early atrial tachyarrhythmia recurrence after ablation. This nomogram may support individualized early post-ablation risk stratification, pending external validation in multicenter cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.